Home » APHTON ANNOUNCES INITIATION OF PHASE I/II TUMOR TREATMENT
APHTON ANNOUNCES INITIATION OF PHASE I/II TUMOR TREATMENT
July 22, 2005
Aphton has announced the enrollment of its first patient in the newly initiated open-label Phase I/II trial of its pipeline compound IGN311. IGN311 is a humanized monoclonal antibody targeting the Lewis Y tumor-associated antigen. Lewis Y is expressed in up to 90 percent of all epithelial cancers, which include breast, colon, gastric and pancreatic cancers.
In a Phase I trial reported earlier this month, IGN311 demonstrated a favorable safety and tolerability profile, and a serum half-life of more than 20 days. In addition, data from the trial suggested that the antibody may be capable of significantly decreasing the number of disseminated tumor cells circulating in peripheral blood.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct